BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago Befesa SA annonce de solides performances au premier trimestre 2025 Efficacité Opérationnelle Augmentation Du Bénéfice Net Expansion Du Marché Prévisions Financières 2025 Résultats Du Premier Trimestre 2025
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago AIXTRON Reports Strong Q1 Amidst Challenging Market Revenue Guidance Innovation Center Free Cash Flow Improvement AIXTRON Q1 2025 Photonics Market Growth
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago AIXTRON annonce un premier trimestre solide dans un marché difficile Centre D'innovation Orientation Des Recettes AIXTRON T1 2025 Croissance Du Marché De La Photonique Amélioration Du Flux De Trésorerie Disponible
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago Baader Bank Doubles Earnings in Q1 2025 Investment Strategy Baader Bank Financial Growth Q1 2025 Earnings Trading Revenue
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago La Baader Bank double ses bénéfices au premier trimestre 2025 Croissance Financière Stratégie D'investissement Banque Baader Résultats Du Premier Trimestre 2025 Revenus Commerciaux
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago Nicox Reports Full Year 2024 Financials Net Loss Cash Reserves Nicox Financial Results VYZULTA Revenue Sale NCX 470 Trials
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago Nicox publie ses résultats financiers pour l'année 2024 Perte Nette Réserves De Trésorerie Résultats Financiers De Nicox Vente De Revenus De VYZULTA Essais NCX 470
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025 Immuno-oncology Personalized Treatment Immune Checkpoint Blockade Gene Expression Signature Cancer Prediction
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago OSE Immunotherapeutics présente une nouvelle signature d'expression génique à l'AACR 2025 Immuno-oncologie Blocage Du Point De Contrôle Immunitaire Signature D'expression Génétique Traitement Personnalisé Prédiction Du Cancer
BRIEF published on 04/30/2025 at 07:35, 1 year 4 months ago ALD Reports Solid First Quarter 2025 Financial Performance and Integration Progress Financial Results Revenue Growth Market Position Integration Progress Quarter 1 2025
Published on 09/08/2026 at 22:30, just now Grid Metals Announces Positive Mineralogical Results at Falcon West, Engages SGS Canada for Ore Sorting Test Work, and Announces Investor Relations Agreements
Published on 09/08/2026 at 22:15, 15 minutes ago GameSquare Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Published on 09/08/2026 at 22:05, 25 minutes ago Loop Industries Appoints Jeff Geygan as Chairman of the Board
Published on 09/08/2026 at 15:40, 6 hours 50 minutes ago CANEX Increases Equity Financing to C$9 Million
Published on 09/08/2026 at 15:00, 7 hours 30 minutes ago Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Published on 09/08/2026 at 22:05, 25 minutes ago oneworld Partners with Popular App Timeshifter to Help Round the World Travellers Beat Jet Lag
Published on 09/08/2026 at 18:30, 4 hours ago Avolta extends long-term travel retail contracts across four Mexican airports
Published on 09/08/2026 at 18:20, 4 hours 10 minutes ago Rönesans Named Among the World's Top 50 International Contractors for the 11th Consecutive Year
Published on 09/08/2026 at 17:45, 4 hours 45 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 août 2026
Published on 09/08/2026 at 17:45, 4 hours 45 minutes ago Chiffre d’affaires semestriel consolidé 2026 : 71,8 M€
Published on 09/08/2026 at 17:45, 4 hours 45 minutes ago Damartex / Résultats de l'exercice 2025-2026
Published on 09/08/2026 at 11:00, 11 hours 30 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 09/08/2026 at 11:00, 11 hours 30 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
